Lilly’s oral obesity drug Foundayo wins FDA approval

The FDA approval of Foundayo is a pivotal fundamental catalyst that bridges the gap between Eli Lilly’s recent aggressive M&A strategy and long-term earnings growth, effectively shifting the narrative from capital expenditure to revenue acceleration. Despite a technical "Oversold" RSI of 22.97, the bullish MACD crossover suggests that the current price of $961.92 is finding a floor, indicating that the recent pullback was a localized consolidation rather than a structural breakdown. The confluence of this approval with the recent $7.8 billion acquisition spree reinforces a robust pipeline, signaling that the stock is poised for a mean reversion toward its 20-day moving average as the market re-prices the valuation based on the oral weight-loss competitive moat. Traders should monitor the $950 support level; if volume remains above the 1.17x average, this provides a high-conviction entry point for a relief rally targeting the $1,010 psychological resistance. Investors should remain cautious of the $935 level, as a breakdown here—despite positive news—would confirm a volume vacuum, indicating institutional selling pressure that outweighs the fundamental tailwinds.